Teva Pharmaceutical Industries Ltd. — Earnings Release 2005

Jan 30, 2006

TEVA

Teva Pharmaceutical Industries Ltd.

Web Site: www.tevapharm.com

Contact: Dan Suesskind Chief Financial Officer Teva Pharmaceutical Industries Ltd. (011) 972-2-589-2840 George Barrett President and CEO Teva North America (215) 591-3030 Liraz Kalif / Kevin Mannix Teva Investor Relations (011) 972-3-926-7554 / (215) 591-8912

TEVA ANNOUNCES GLOBAL IN-MARKET FOURTH QUARTER SALES OF ITS BLOCKBUSTER COPAXONE® INCREASED 24% TO $323 MILLION

ANNUAL SALES INCREASED 26% TO RECORD $1.18 BILLION

Jerusalem, Israel, January 30, 2006 – Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group’s financial results, that global in-market sales of Copaxone® reached $323 million in the fourth quarter ended December 31, 2005, an increase of 24% over the comparable quarter of 2004. For the full year 2005, global in-market sales of Copaxone® reached an all-time high of $1,176 million, an increase of 26% over 2004.

U.S. sales in the fourth quarter 2005 increased 26% over the fourth quarter 2004 to $220 million. For the full year 2005, U.S. sales increased 25% to $782 million compared to last year.

According to IMS data in the US, Copaxone® continued to strengthen its position as market leader reaching an all time record of 34.3% in TRx share and 35.2% in NRx share in December 2005.

For the fourth quarter 2005, sales outside the U.S., mainly in Europe, increased by 19% over the comparable quarter of 2004, to $103 million. For the entire year, sales outside the U.S. increased by 27% to $394 million.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva’s sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition of IVAX Corporation will be consummated and the terms of any conditions imposed in connection with such closing, the terms and conditions of the financing utilized by Teva for the IVAX acquisition, Teva’s ability to rapidly integrate IVAX’s operations and achieve expected synergies, Teva’s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive

---

generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final court decision, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

• 2 -

---

מבט תעשיות פרמצבטיות בע"מ

IFA

2006, בינואר 30

טבע מודיעה כי המכירות הגלובליות של קופקסון®, במונחי מכירה לשוק, ברבעון הרביעי של 2005 עלו ב- 24% והסתכמו ב- 323 מיליון $

המכירות השנתיות עלו ב- 26% לשיא של 1.18 מיליארד $

טבע מודיעה, בהמשך לפרסום התוצאות הכספיות של Sanofi-Aventis, כי המכירות הגלובליות של קופקסון®, במונחי מכירה לשוק, הסתכמו ברבעון הרביעי שהסתיים ב- 31 בדצמבר 2005, ב- 323 מיליון $, גידול של 24% לעומת הרבעון המקביל בשנת 2004. המכירות הגלובליות של קופקסון® במונחי מכירה לשוק בשנת 2005 כולה, הגיעו לשיא של כל הזמנים - 1,176 מיליון $, גידול של 26% לעומת שנת 2004.

מכירות הקופקסון® בארה"ב, ברבעון הרביעי של 2005, גדלו ב- 26% לעומת הרבעון המקביל ב- 2004 והסתכמו ב- 220 מיליון $. המכירות בשנת 2005 כולה, גדלו ב- 25% ביחס למכירות בשנת 2004 והסתכמו ב- 782 מיליון $.

לפי נתוני ה- IMS בארה"ב, קופקסון® המשיך לחזק את מעמדו כמוביל שוק והגיע לנתח שוק מסך כל המרשמים בארה"ב (TRx) של 34.3%, שיא של כל הזמנים ו- 35.2% במונחי מרשמים חדשים בדצמבר 2005.

המכירות מחוץ לארה"ב, בעיקר באירופה, צמחו ברבעון הרביעי של 2005 ב- 19% לעומת הרבעון המקביל אשתקד והסתכמו ב- 103 מיליון $. בכל שנת 2005, עלו המכירות מחוץ לארה"ב ב- 27% והסתכמו ב- 394 מיליון $.

טבע תעשיות פרמצבטיות בע"מ הינה חברה גלובלית שבסיסה בישראל ואחת מ- 20 החברות הפרמצבטיות המובילות בעולם. טבע, המתמחה בייצור תרופות גנריות וייחודיות ובייצור חומרים פעילים לתעשיה הפרמצבטית, הינה אחת מהמובילות בעולם בתחום הגנריקה. לטבע אתרי ייצור, מחקר, שיווק והפצה בישראל, בצפון ובמרכז אמריקה ובאירופה. קרוב ל- 90% ממכירותיה של הקבוצה הן לצפון אמריקה ואירופה.

---

להלן הסעיף הידוע בארה"ב כ- Safe Harbor בנוסחו האנגלי ואשר מטרתו להגן על החברה, עפ"י הדין האמריקאי:

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include whether and when the proposed acquisition of IVAX Corporation will be consummated and the terms of any conditions imposed in connection with such closing, the terms and conditions of the financing utilized by Teva for the IVAX acquisition, Teva's ability to rapidly integrate IVAX's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final court decision, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

liraz.kalif@teva.co.il

03-9267281 פקס-תיקון 49131 מ.ד. 3190 פח-תיקון פקס-טלפון 03-9267519

Web site: www.tevapharm.com